Comparative Pharmacology
Head-to-head clinical analysis: KONVOMEP versus VIGABATRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KONVOMEP versus VIGABATRIN.
KONVOMEP vs VIGABATRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosnetupitant is a neurokinin-1 (NK1) receptor antagonist that inhibits substance P binding; palonosetron is a serotonin-3 (5-HT3) receptor antagonist that blocks emetic signals in the chemoreceptor trigger zone and gastrointestinal tract.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
IV: 8 mg (as netupitant 235 mg/palonosetron 0.25 mg combination) over 15 minutes on day 1 of chemotherapy.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults. Extended to 18-24 hours in renal impairment (CrCl <30 mL/min).
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Renal: approximately 70% as unchanged drug; fecal: approximately 20% as metabolites; biliary: negligible.
Renal: ~80% unchanged in urine; fecal: <5%.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."